Citation Impact
Citing Papers
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation
2006
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
2007
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
2006
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
2013 Standout
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
2010
Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells
2006
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
2006
Treatment of kidney cancer
2009 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272
2006
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Targeting ADAMS and ERBBs in lung cancer
2006
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
2012
Opportunities and challenges in the development of kinase inhibitor therapy for cancer
2003
Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy
2013
EGFR Antagonists in Cancer Treatment
2008 Standout
A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
2006
A view on drug resistance in cancer
2019 StandoutNature
Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib
2007
Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
2008
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Comparing antibody and small-molecule therapies for cancer
2006
Sensitization of Tumor to 212Pb Radioimmunotherapy by Gemcitabine Involves Initial Abrogation of G2 Arrest and Blocked DNA Damage Repair by Interference With Rad51
2012
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Molecular mechanisms of drug resistance
2005
Lymphatic endothelium in health and disease
2008
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Lung Cancer
2008 Standout
Glioblastoma and Other Malignant Gliomas
2013 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Lymphangiogenesis: Molecular Mechanisms and Future Promise
2010 Standout
Head and neck cancer
2008 Standout
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
The HER family and cancer: emerging molecular mechanisms and therapeutic targets
2007
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
2013
Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
2010 Standout
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
2014 Standout
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancer
2004
ErbBs in lung cancer
2008
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer
2005
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas
2010
Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer
2005
A Translational View of the Molecular Pathogenesis of Lung Cancer
2007
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Malignant Gliomas in Adults
2008 Standout
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
2007
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Where next for gefitinib in patients with lung cancer?
2006
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
2008
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
2008
Primary brain tumours in adults
2012 Standout
Pancreatic Cancer
2010 Standout
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases
2010
Clinical pharmacokinetics of tyrosine kinase inhibitors
2009
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
2008
Predicting the outcome of chemotherapy for lung cancer
2006
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Gefitinib for non-small-cell lung cancer treatment
2011
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010
Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells
2013
Overview of the Tolerability of Gefitinib (IRESSA???) Monotherapy
2004
Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations
2006
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
2008
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
2006
Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study
2005
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Blockade of Epidermal Growth Factor Receptors Chemosensitizes Breast Cancer Cells through Up-Regulation of Bnip3L
2005
Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib
2007
Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer
2007
EGFR Mutations in Non–Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment
2005
Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer
2005
Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib
2006
Diagnosis and Treatment of Recurrent High-Grade Astrocytoma
2006
A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma
2004
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
2004
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2008
Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non–Small Cell Lung Cancer
2005
Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence
2005
Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
2005
End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
2009
Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer
2005
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
2008
Cancer Genome Landscapes
2013 StandoutScience
Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
2005
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas
2005
Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines
2006
Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
2008
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance
2008
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
2010 Standout
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
2008
CNS Metastases in Breast Cancer
2004
Works of Stefania Bartolini being referenced
Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial
2007
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
2005
Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC
2003
Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma
2004
Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer
2004
Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
2004
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
2003
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib
2006
Emerging drugs for non-small cell lung cancer
2003
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial
2004
Role of gemcitabine in cancer therapy
2005
Clinical experience with gefitinib: An update
2006
Lymphangiogenesis in Crohn’s disease: an immunohistochemical study using monoclonal antibody D2-40
2007
IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients
2005
MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
2008
ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases
2003